HY Results – Group revenue increased by 10% but adjusted EBITDA decreased by 1% and the adjusted EBITDA margin fell to 14.2% from 15.8%), reflecting revenue impact and increased operating expenses. Adjusted earnings and adjusted earnings per share decreased by 15%. HEPS came in at 11.3 pence from 8.8 pence previously. The leverage ratio climbed to 4.4x (FY22: 3.9x), and no interim dividend declared in light of a current offer for Mediclinic by Remgro and co.
Click here to read the SENS